Advanced Disease Clinical Trial
— Palli-MONITOROfficial title:
Palli-MONITOR: A Phase II Mixed-Methods Study to Implement and Test the Electronic Version of the Integrated Palliative Care Outcome Scale (eIPOS) in an Specialist Palliative Home Care
Verified date | April 2023 |
Source | Ludwig-Maximilians - University of Munich |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
In palliative care, the Integrated Palliative Care Outcome Scale (IPOS) is widely used as a patient reported outcome measure (PROM) and covers patients' main concerns, common symptoms, patient and family distress, existential wellbeing, sharing feelings with family, information received, and practical concerns. The IPOS is validated for patients with advanced cancer or non-cancer disease and is available as patients and professional carer version. The implementation of a PROM in the home care setting is more challenging compared to the inpatient setting. Palli-MONITOR will develop, implement and test the feasibility of an internet-based real-time monitoring of palliative needs of patients with advanced diseases using the electronic version of IPOS (eIPOS) including a clinical decision support tool for specialist palliative home care. The project is conducted in two parts: 1. A pilot study to develop an electronical monitoring that is acceptable for both palliative patients and professionals of specialist palliative home care teams. 2. A feasibility study to implement and test eIPOS in specialist palliative home care teams.
Status | Completed |
Enrollment | 82 |
Est. completion date | March 31, 2022 |
Est. primary completion date | August 31, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Participants cared for by one of the participating specialist palliative home care teams - Participants who have the capacity to give informed consent to participate the study in writing and are able to participate in research - Participants who are not too distressed or ill to participate in the study Exclusion Criteria: - Participants with cognitive impairment |
Country | Name | City | State |
---|---|---|---|
Germany | Katerina Hriskova | München | Bavaria |
Lead Sponsor | Collaborator |
---|---|
Ludwig-Maximilians - University of Munich |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Recruitment rates | The recruitment rates of each specialist palliative home care teams will be calculated as the percentage of eligible participants who agreed to participate in the study divided by the total number of eligible participants approached to participate in the study. | 1 year | |
Primary | Acceptance of electronical monitoring | Based on qualitative data | up to 4 weeks after enrollment | |
Primary | Technical feasibility of electronical monitoring: Integrated Palliative Care Outcome Scale | Completeness of the electronic Integrated Palliative Care Outcome Scale (eIPOS). IPOS includes 10 symptoms and 7 questions on patients and carers emotional situation, spiritual concerns, and provision of information and support. Five answer options for each question are possible (scored 0 to 4; higher scores indicate higher burden). The overall IPOS score is the sum of the scores from each of the 17 questions. The overall IPOS score can therefore range from zero to 68. | up to 4 weeks after enrollment | |
Primary | Influence of electronical monitoring on provided care | Assess care modifications consecutive of initial care | up to 4 weeks after enrollment | |
Secondary | Palliative needs (IPOS) | Change in palliative care needs and specific symptoms assessed with the Integrated Palliative Care Outcome Scale (IPOS). IPOS includes 10 symptoms and 7 questions on patients and carers emotional situation, spiritual concerns, and provision of information and support. Five answer options for each question are possible (scored 0 to 4; higher scores indicate higher burden). The overall IPOS score is the sum of the scores from each of the 17 questions. The overall IPOS score can therefore range from zero to 68. | up to 4 weeks after enrollment | |
Secondary | EORTC QLQ-C15-PAL | Change from baseline in quality of life (at 2 weeks) assessed with the European Organization for Research and Treatment of Cancer (EORTC) questionnaire of life quality (QLQ). The adapted version for palliative (PAL) cancer care patients will be used.
One item, scored from 1 to 7 (higher scores indicate better quality of life), gives an overall score corresponding to the quality of life that the patient feels he or she has. |
At baseline and 2 weeks | |
Secondary | Symptom burden (ESAS) | Change from baseline in symptom burden (at 2 weeks) assessed with the Edmonton Symptom Assessment Scale (ESAS). ESAS includes 9 common symptoms. The severity of each symptom is rated from 0 to 10 on a numerical scale (higher scores indicate higher intensity). | At baseline and 2 weeks | |
Secondary | Unplanned hospital submissions | Number of patients with unplanned hospitalization, assessed from medical record | up to 3 weeks after enrollment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01209676 -
IMCgp100 in Advanced Unresectable Melanoma
|
Phase 0 | |
Terminated |
NCT01215578 -
Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors
|
Phase 2 | |
Withdrawn |
NCT02496832 -
A Study of Hypoxia Imaging in Advanced Pancreatic Cancer Patients Being Treated With Gemcitabine and TH-302 or TH-302 Placebo
|
N/A |